{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:42:00Z","timestamp":1785552120502,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The studies were supported by KeyMed Biosciences (Chengdu) Co.,Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02887-w","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:03:06Z","timestamp":1717488186000},"page":"2953-2965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct06161090","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct0489394","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Libo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"8 Suppl","key":"2887_CR1","first-page":"S115","volume":"23","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115\u201323.\u00a0https:\/\/www.ajmc.com\/view\/overview-of-atopic-dermatitis-article\/. Accessed 2024\u00a0Jan 17.","journal-title":"Am J Manag Care"},{"issue":"3","key":"2887_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allerg Asthma Immunol. 2018;121(3):340\u20137. https:\/\/doi.org\/10.1016\/j.anai.2018.07.006.","journal-title":"Ann Allerg Asthma Immunol"},{"issue":"2","key":"2887_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.aller.2012.03.001","volume":"41","author":"J Mallol","year":"2013","unstructured":"Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol. 2013;41(2):73\u201385. https:\/\/doi.org\/10.1016\/j.aller.2012.03.001.","journal-title":"Allergol Immunopathol"},{"issue":"8","key":"2887_CR4","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms22084130","volume":"22","author":"J Sroka-Tomaszewska","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. https:\/\/doi.org\/10.3390\/ijms22084130.","journal-title":"Int J Mol Sci"},{"key":"2887_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107985","volume":"99","author":"P-F Clot","year":"2021","unstructured":"Clot P-F, Kamal M, Sun J, et al. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: results of two randomized, double-blind, placebo-controlled studies. Int Immunopharmacol. 2021;99:107985. https:\/\/doi.org\/10.1016\/j.intimp.2021.107985.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2887_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.17791","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator\u2019s Global Assessment: a pooled analysis of data from two phase\u00a0III trials. Br J Dermatol. 2019;181(1):80\u20137. https:\/\/doi.org\/10.1111\/bjd.17791.","journal-title":"Br J Dermatol"},{"issue":"25","key":"2887_CR7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2205982.","journal-title":"N Engl J Med"},{"key":"2887_CR8","unstructured":"European Medicines Agency. Dupixent (dupilumab). Summary of product characteristics. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190506144541\/anx_144541_en.pdf. Accessed 2024 Jan 17."},{"key":"2887_CR9","unstructured":"Food and Drug Administration. Dupixent (dupilumab). Highlights of prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 2024 Jan 17."},{"key":"2887_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102076","volume":"61","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yan B, Shen S, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase\u00a02 clinical trial. EClinicalMedicine. 2023;61:102076. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102076.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2887_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","volume":"9","author":"Z Li","year":"2020","unstructured":"Li Z, Radin A, Li M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev. 2020;9(6):742\u201355. https:\/\/doi.org\/10.1002\/cpdd.798.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2887_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2199-7-45","volume":"7","author":"K Liddiard","year":"2006","unstructured":"Liddiard K, Welch JS, Lozach J, Heinz S, Glass CK, Greaves DR. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol. 2006;7:45.\u00a0https:\/\/doi.org\/10.1186\/1471-2199-7-45.","journal-title":"BMC Mol Biol"},{"issue":"6","key":"2887_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/advances\/nmaa074","volume":"11","author":"DPS Lee","year":"2020","unstructured":"Lee DPS, Low JHM, Chen JR, Zimmermann D, Actis-Goretta L, Kim JE. The influence of different foods and food ingredients on acute postprandial triglyceride response: a systematic literature review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11(6):1529\u201343. https:\/\/doi.org\/10.1093\/advances\/nmaa074.","journal-title":"Adv Nutr"},{"issue":"2","key":"2887_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase\u00a03 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"issue":"10013","key":"2887_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase\u00a02b trial. Lancet. 2016;387(10013):40\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8.","journal-title":"Lancet"},{"key":"2887_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002747","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase\u00a02b trial. Chin Med J. 2023. https:\/\/doi.org\/10.1097\/CM9.0000000000002747.","journal-title":"Chin Med J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02887-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02887-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02887-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:42:01Z","timestamp":1719571321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02887-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2887"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02887-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Libo Zhang, Weilong Zhang, Yufeng Xu, Yingmin Jia, and Zhichuan Li are employees of Keymed Biosciences (Chengdu) Co.,Ltd. Bo Chen is a shareholder of Keymed Biosciences (Chengdu) Co.,Ltd. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocols and amendments for both trials were reviewed and approved by the ethics committees at each clinical trial site. Both studies were conducted in accordance with the Good Clinical Practice (GCP) guidelines and the principles of the Declaration of Helsinki. All subjects signed written informed consent prior to their participation in the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}